News
AZ's Truqap and Roche assay cleared for PTEN prostate cancer
AstraZeneca has claimed a second approval for AKT inhibitor Truqap, in prostate cancer, that should help achieve its blockbuster hopes for the drug.
Oncology
Bridging the cancer drug development gap: AI-driven precisio...
Functional precision oncology gives physicians the data they need to make better decisions about each patient’s care.
News
Pushy NHS chatbots 'can put patients off screening'
Amid the push to digitise the UK health service, a study has sounded a note of caution about entrusting important patient appointments to chatbots.
Oncology
ASCO 2026: Are radiopharmaceuticals being systematically und...
The maximum dose of radiation prescribed by the FDA may be too conservative for novel therapies. But there's no easy solution to finding a new limit.
Oncology
ASCO 2026: Takeda’s Innovent deal bears fruit, with Teresa B...
Teresa Bitetti and PK Morrow share some of the highlights from Takeda’s data at the show as well as discussing how it fits into their larger strategy.
News
Views & Analysis
Deep Dive
Editor's Picks
Editor's Picks
